Trial Outcomes & Findings for A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis (NCT NCT00951275)
NCT ID: NCT00951275
Last Updated: 2017-08-03
Results Overview
Hemoglobin levels were measured as grams/deciliter (g/dL).
COMPLETED
PHASE3
105 participants
Week 4
2017-08-03
Participant Flow
Participant milestones
| Measure |
Tocilizumab 8 mg/kg
Participants received tocilizumab 8 milligrams per kilogram (mg/kg) (maximum dose 800 mg) intravenously (IV) once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Overall Study
STARTED
|
105
|
|
Overall Study
COMPLETED
|
92
|
|
Overall Study
NOT COMPLETED
|
13
|
Reasons for withdrawal
| Measure |
Tocilizumab 8 mg/kg
Participants received tocilizumab 8 milligrams per kilogram (mg/kg) (maximum dose 800 mg) intravenously (IV) once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Overall Study
Administrative Reason
|
1
|
|
Overall Study
Adverse Event
|
7
|
|
Overall Study
Withdrawal by Subject
|
4
|
|
Overall Study
Protocol Violation
|
1
|
Baseline Characteristics
A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Baseline characteristics by cohort
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Age, Continuous
|
55.0 years
STANDARD_DEVIATION 12.8 • n=99 Participants
|
|
Sex: Female, Male
Female
|
89 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Week 4Population: ITT population
Hemoglobin levels were measured as grams/deciliter (g/dL).
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=101 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Improvement of Anemia at Week 4 Assessed as Change From Baseline in Hemoglobin
|
0.40 g/dL
Standard Deviation 0.78
|
PRIMARY outcome
Timeframe: Week 4Population: ITT population; n=number of participants assessed for the specified parameter at a given visit.
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=101 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Improvement in Fatigue at Week 4 Assessed as Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores
|
8.76 units on a scale
Standard Deviation 8.83
|
SECONDARY outcome
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24Population: ITT population; n=number of participants assessed for the specified parameter at a given visit.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Mean Hemoglobin Levels During the Study
Baseline (n=105)
|
12.41 g/dL
Standard Deviation 1.51
|
|
Mean Hemoglobin Levels During the Study
Week 2 (n=99)
|
12.84 g/dL
Standard Deviation 1.47
|
|
Mean Hemoglobin Levels During the Study
Week 4 (n=101)
|
12.79 g/dL
Standard Deviation 1.44
|
|
Mean Hemoglobin Levels During the Study
Week 8 (n=100)
|
12.95 g/dL
Standard Deviation 1.45
|
|
Mean Hemoglobin Levels During the Study
Week 12 (n=94)
|
13.06 g/dL
Standard Deviation 1.49
|
|
Mean Hemoglobin Levels During the Study
Week 16 (n=95)
|
13.10 g/dL
Standard Deviation 1.42
|
|
Mean Hemoglobin Levels During the Study
Week 20 (n=90)
|
13.13 g/dL
Standard Deviation 1.40
|
|
Mean Hemoglobin Levels During the Study
Week 24/End of Study (n=100)
|
13.12 g/dL
Standard Deviation 1.39
|
SECONDARY outcome
Timeframe: Weeks 2, 4, 8, 12, 16, 20, and 24Population: ITT population; n=number of participants assessed for the specified parameter at a given visit.
Improvement of anemia was evaluated as change in hemoglobin levels from baseline.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Week 2 (n=99)
|
0.47 g/dL
Standard Deviation 0.69
|
|
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Week 4 (n=101)
|
0.40 g/dL
Standard Deviation 0.78
|
|
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Week 8 (n=100)
|
0.56 g/dL
Standard Deviation 0.95
|
|
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Week 12 (n=94)
|
0.64 g/dL
Standard Deviation 1.04
|
|
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Week 16 (n=95)
|
0.62 g/dL
Standard Deviation 1.08
|
|
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Week 20 (n=90)
|
0.67 g/dL
Standard Deviation 1.10
|
|
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Week 24/End of Study (n=100)
|
0.64 g/dL
Standard Deviation 1.20
|
SECONDARY outcome
Timeframe: Baseline, Weeks 2, 4, 8,12, 16, 20 and 24Population: ITT population; n=number of participants assessed for the specified parameter at a given visit.
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a ≥5-point change from Baseline.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
FACIT-F Scores
Baseline (n=105)
|
28.60 units on a scale
Standard Deviation 9.77
|
|
FACIT-F Scores
Week 2 (n=102)
|
35.54 units on a scale
Standard Deviation 8.53
|
|
FACIT-F Scores
Week 4 (n=101)
|
37.24 units on a scale
Standard Deviation 8.46
|
|
FACIT-F Scores
Week 8 (n=102)
|
39.16 units on a scale
Standard Deviation 7.35
|
|
FACIT-F Scores
Week 12 n=94
|
39.02 units on a scale
Standard Deviation 8.01
|
|
FACIT-F Scores
Week 16 (n=97)
|
40.21 units on a scale
Standard Deviation 7.87
|
|
FACIT-F Scores
Week 20 (n=91)
|
40.05 units on a scale
Standard Deviation 7.77
|
|
FACIT-F Scores
Week 24/End of Study (n=102)
|
39.69 units on a scale
Standard Deviation 8.39
|
SECONDARY outcome
Timeframe: Weeks 2, 4, 8, 12, 16, 20 and 24Population: ITT population; n=number of participants assessed for the specified parameter at a given visit.
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a ≥5-point change from Baseline.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=102 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Week 2 (n=102)
|
7.11 units on a scale
Standard Deviation 8.40
|
|
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Week 4 (n=101)
|
8.76 units on a scale
Standard Deviation 8.83
|
|
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Week 8 (n=102)
|
10.74 units on a scale
Standard Deviation 9.49
|
|
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Week 12 (n=94)
|
10.60 units on a scale
Standard Deviation 10.13
|
|
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Week 16 (n=97)
|
11.47 units on a scale
Standard Deviation 10.24
|
|
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Week 20 (n=91)
|
11.63 units on a scale
Standard Deviation 10.22
|
|
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Week 24/End of Study (n=102)
|
10.84 units on a scale
Standard Deviation 11.00
|
SECONDARY outcome
Timeframe: Week 24Population: ITT Population
The ACR response rates ACR20, ACR50, and ACR70 were defined as ≥20%, ≥50% and ≥ 70% improvement, respectively, in: swollen joint count (SJC) (66 joints) and tender joint count (TJC) (68 joints) and 3 of the 5 remaining ACR parameters: Patient assessment of pain; Patient Global Assessment of Disease Activity; Investigator Global Assessment of Disease Activity; participant self-rated assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI); and acute phase response (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]).
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Improvement
ACR20
|
81.0 percentage of participants
Interval 73.44 to 88.46
|
|
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Improvement
ACR50
|
59.0 percentage of participants
Interval 49.64 to 68.45
|
|
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Improvement
ACR70
|
42.9 percentage of participants
Interval 33.39 to 52.32
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
Sixty-eight (68) joints were assessed at each visit for tenderness; joints were assessed and classified as tender/not tender. Tender joint count 68 (TJC-68) was calculated as the number of tender joints from 68 joints; the number of tender joints was summed (maximum score 68). Calculated values were used for the analysis. A negative score indicated improvement.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=102 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in TJC
|
-70.65 percent change in tender joints
Standard Deviation 47.71
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
Sixty-six (66) joints were assessed at each visit for swelling; joints were assessed and classified as swollen/not swollen. Swollen joint count 66 (SJC-66) was calculated as the number of swollen joints from 66 joints; the number of swollen joints was summed (maximum score 66). Calculated values were used for the analysis. A negative score indicated improvement.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=100 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in SJC
|
-77.59 percent change in swollen joints
Standard Deviation 31.22
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
The participant's assessment of their current level of pain was displayed on a 100-millimeter (mm) horizontal visual analog scale (VAS). The left-hand extreme of the line was described as "no pain" and the right-hand as "unbearable pain". The participant was asked to mark the line that corresponded to their current level of pain; the distance from the left edge was recorded.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=100 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in Patient Global Assessment of Pain
|
-52.25 percent change in mm
Standard Deviation 56.88
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
The participant's overall assessment of their current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme as "maximum disease activity" (maximum arthritis disease activity). Participants were asked to assess their current level of disease activity and mark the line; the distance from the left edge was recorded.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=103 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in Patient's Global Assessment of Disease Activity
|
-55.43 percent change in mm
Standard Deviation 56.12
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
The physician's assessment of the participant's current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme was considered "maximum disease activity". The physician's global assessment of disease activity was completed by the Efficacy Assessor who could or could not be a physician. The assessor was asked to mark the line corresponding to their assessment of the participant's present level of disease activity; the distance from the left edge was recorded.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=103 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in Investigator's Global Assessment of Disease Activity
|
-65.89 percent change in mm
Standard Deviation 36.72
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Overall score was computed as the sum of the domain scores and divided by the number of domains answered. Total possible score range was 0-3 where 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=101 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in HAQ-DI
|
-45.94 percent change from baseline
Standard Deviation 54.17
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
hs-CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). hsCRP is measured in milligrams per liter (mg/L).
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=98 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in High-Sensitivity CRP (Hs-CRP)
|
-53.33 percent change in mg/L
Standard Deviation 149.9
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
ESR is a blood test used to monitor therapy in inflammatory diseases such as RA and reflects acute phase reactant levels. ESR is measured in mm per hour (mm/hr); active disease in RA is defined by an ESR greater than 30 mm/hr.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=98 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in ESR
|
-66.00 percent change in mm/hr
Standard Deviation 47.73
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
Disease response was assessed using EULAR Disease Activity Score Based on 28-Joint Count (DAS28) categories of Good, Moderate, or No Response. Good response was defined as a DAS28 score of less than (\<)3.2 and improvement from baseline of \>1.2; Moderate response was defined as a DAS28 score of 3.2-5.1 and improvement from baseline of 1.2-0.6 or a DAS28 score of \>5.1 and improvement from baseline of \>1.2; No response was defined as a DAS28 score of \>5.1 and improvement from baseline of \<1.2. Participants who discontinued prematurely were identified as non-responders.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percentage of Participants With a Response at Week 24 by European League Against Rheumatism (EULAR) Category
No Response
|
12.4 percentage of participants
Interval 6.08 to 18.68
|
|
Percentage of Participants With a Response at Week 24 by European League Against Rheumatism (EULAR) Category
Moderate Response
|
23.8 percentage of participants
Interval 15.66 to 31.96
|
|
Percentage of Participants With a Response at Week 24 by European League Against Rheumatism (EULAR) Category
Good Response
|
63.8 percentage of participants
Interval 54.62 to 73.0
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
DAS28 calculated from the number of swollen joints (SJC) and tender joints (TJC) using the 28 joints count, the ESR (mm/hr) and patient's global assessment of disease activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2=low disease activity, DAS28 \>5.1=high disease activity and DAS \<2.6=remission.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percentage of Participants With a Response at Week 24 by DAS28 Category
DAS28 <2.6
|
49.5 percentage of participants
Interval 39.96 to 59.09
|
|
Percentage of Participants With a Response at Week 24 by DAS28 Category
DAS28 ≥2.6
|
50.5 percentage of participants
Interval 40.91 to 60.04
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
DAS28 calculated from the number of swollen joints (SJC) and tender joints (TJC) using the 28 joints count, the ESR (mm/hr) and patient's global assessment of disease activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2=low disease activity, DAS28 \>5.1=high disease activity and DAS \<2.6=remission.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=97 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percent Change From Baseline to Week 24 in DAS28 Score
|
-55.78 percent change from baseline
Standard Deviation 23.49
|
SECONDARY outcome
Timeframe: Week 24Population: ITT population
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=105 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Percentage of Participants With an Improvement of ≥1 g/dL in Hemoglobin
|
31.4 percentage of participants
Interval 22.55 to 40.31
|
SECONDARY outcome
Timeframe: BaselinePopulation: ITT population; n=number of participants assessed for the specified parameter.
The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consists of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=25 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Number of Days as Assessed by Short Form-Health and Labour Questionnaire (SF-HLQ)
Missed working days (n=25)
|
3.6 days
Standard Deviation 5.0
|
|
Number of Days as Assessed by Short Form-Health and Labour Questionnaire (SF-HLQ)
Days with reduced capacity (n=19)
|
11.8 days
Standard Deviation 8.8
|
SECONDARY outcome
Timeframe: Weeks 12 and 24Population: ITT population; n=number of participants assessed for the specified parameter.
The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consists of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=25 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Change From Baseline to Weeks 12 and 24 in Number of Days as Assessed by SF-HLQ
Missed working days, Week 24 (n=25)
|
-3.3 days
Standard Deviation 5.1
|
|
Change From Baseline to Weeks 12 and 24 in Number of Days as Assessed by SF-HLQ
Missed working days, Week 12 (n=25)
|
-3.5 days
Standard Deviation 5.1
|
|
Change From Baseline to Weeks 12 and 24 in Number of Days as Assessed by SF-HLQ
Days with reduced capacity, Week 12 (n=19)
|
-4.2 days
Standard Deviation 10.9
|
|
Change From Baseline to Weeks 12 and 24 in Number of Days as Assessed by SF-HLQ
Days with reduced capacity, Week 24 (n=19)
|
-6.1 days
Standard Deviation 10.7
|
SECONDARY outcome
Timeframe: BaselinePopulation: ITT population; n=number of participants assessed for the specified parameter.
Number of working hours lost, and number of hours of support in in taking over and performing usual household tasks in the last month: chores done by family members, chores done by other persons receiving no pay, home care, other paid care, total number of unpaid hours, and total number of hours during the last month were reported.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=77 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Number of Hours as Assessed by SF-HLQ
Work lost (n=17)
|
13.6 hours
Standard Deviation 19.8
|
|
Number of Hours as Assessed by SF-HLQ
Chores by family (n=77)
|
10.3 hours
Standard Deviation 26.5
|
|
Number of Hours as Assessed by SF-HLQ
Chores by other unpaid person (n=77)
|
0.2 hours
Standard Deviation 0.8
|
|
Number of Hours as Assessed by SF-HLQ
Home care (n=77)
|
0.0 hours
Standard Deviation 0.0
|
|
Number of Hours as Assessed by SF-HLQ
Other paid care (n=77)
|
1.1 hours
Standard Deviation 4.2
|
|
Number of Hours as Assessed by SF-HLQ
Total unpaid (n=77)
|
10.4 hours
Standard Deviation 26.5
|
|
Number of Hours as Assessed by SF-HLQ
Total (n=77)
|
11.5 hours
Standard Deviation 26.4
|
SECONDARY outcome
Timeframe: BaselinePopulation: ITT population; n=number of participants assessed for the specified parameter.
Number of working hours lost, and number of hours of support in in taking over and performing usual household tasks in the last month: chores done by family members, chores done by other persons receiving no pay, home care, other paid care, total number of unpaid hours, and total number of hours during the last month were reported. Changes from baseline were only calculated in participants who completed the questionnaire at all times (baseline, Week 12, and Week 24). Negative number indicates improvement.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=77 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Total, Week 12 (n=77)
|
-2.7 hours
Standard Deviation 31.7
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Work lost, Week 12 (n=17)
|
-8.9 hours
Standard Deviation 15.2
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Work lost, Week 24 (n=17)
|
-12.1 hours
Standard Deviation 20.3
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Chores by family, Week 12 (n=77)
|
-4.4 hours
Standard Deviation 27.4
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Chores by family, Week 24 (n=77)
|
-3.2 hours
Standard Deviation 32.0
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Chores by other unpaid person, Week 12 (n=77)
|
-0.1 hours
Standard Deviation 0.8
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Chores by other unpaid person, Week 24 (n=77)
|
-0.2 hours
Standard Deviation 0.8
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Other paid care, Week 12 (n=77)
|
1.8 hours
Standard Deviation 15.5
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Other paid care, Week 24 (n=77)
|
-0.1 hours
Standard Deviation 5.1
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Total unpaid, Week 12 (n=77)
|
-4.5 hours
Standard Deviation 27.3
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Total unpaid, Week 24 (n=77)
|
-3.6 hours
Standard Deviation 32.0
|
|
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Total, Week 24 (n=77)
|
-3.7 hours
Standard Deviation 32.4
|
SECONDARY outcome
Timeframe: BaselinePopulation: ITT population; n=number of participants assessed for the specified parameter.
Participants were asked if their health problems hindered their paid work on a scale of 1 to 3 (1=no, 2=yes, slightly, 3=yes, very much) and their unpaid work including household work, going shopping, odd jobs, specific activities sharing the household on a scale of 0 to 3 (0=performed without being bothered by healthy problems; 1=performed although bothered by health problems; 2=not performed because of health problems; 3=not performed for reasons other than health problems). The total hindrance score for unpaid work was derived by adding up the item scores. This hindrance score is a measure of the hindrance experienced as a result of health problems during the performance of unpaid work. The minimum score per item for hindrance score was 0, maximum score was 2 (Score of 3 was not considered since the reasons were "other than health problems"). Total score was calculated by adding all 4 items together and ranged from 0 (best possible score) to 8 (worst possible score).
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=85 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
SF-HLQ Hindrance Score
Paid work (n=23)
|
0.9 units on a scale
Standard Deviation 0.5
|
|
SF-HLQ Hindrance Score
Household work (n=84)
|
1.1 units on a scale
Standard Deviation 0.5
|
|
SF-HLQ Hindrance Score
Going shopping (n=84)
|
1.0 units on a scale
Standard Deviation 0.6
|
|
SF-HLQ Hindrance Score
Odd jobs (n=84)
|
1.1 units on a scale
Standard Deviation 0.7
|
|
SF-HLQ Hindrance Score
Activities for/with children (n=85)
|
0.6 units on a scale
Standard Deviation 0.6
|
|
SF-HLQ Hindrance Score
Total score (n=84)
|
3.7 units on a scale
Standard Deviation 1.7
|
SECONDARY outcome
Timeframe: BaselinePopulation: ITT population; n=number of participants assessed for the specified parameter.
Participants were asked if health problems hindered their paid work on a scale of 1 to 3 (1=no, 2=yes, slightly, 3=yes, very much) and their unpaid work including household work, going shopping, odd jobs, specific activities sharing the household on a scale of 0 to 3 (0=performed without being bothered by healthy problems; 1=performed although bothered by health problems; 2=not performed because of health problems; 3=not performed for reasons other than health problems). Hindrance score is a measure of the hindrance experienced as a result of health problems during the performance of unpaid work. The minimum score per item for hindrance score was 0, maximum score was 2 (Score of 3 was not considered since the reasons were "other than health problems"). Total score was calculated by adding all 4 items together and ranged from 0 (best possible score) to 8 (worst possible score). A negative change from baseline indicates improvement.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=85 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Paid work, Week 12 (n=23)
|
-0.30 units on a scale
Standard Deviation 0.70
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Paid work, Week 24 (n=23)
|
-0.39 units on a scale
Standard Deviation 0.58
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Household work, Week 12 (n=84)
|
-0.40 units on a scale
Standard Deviation 0.70
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Household work, Week 24 (n=84)
|
-0.40 units on a scale
Standard Deviation 0.68
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Going shopping, Week 12 (n=84)
|
-0.40 units on a scale
Standard Deviation 0.64
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Going shopping, Week 24 (n=84)
|
-0.40 units on a scale
Standard Deviation 0.62
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Odd jobs, Week 12 (n=84)
|
-0.38 units on a scale
Standard Deviation 0.79
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Odd jobs, Week 24 (n=84)
|
-0.36 units on a scale
Standard Deviation 0.83
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Activities for/with children, Week 12 (n=85)
|
-0.16 units on a scale
Standard Deviation 0.69
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Activities for/with children, Week 24 (n=85)
|
-0.24 units on a scale
Standard Deviation 0.70
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Total score, Week 12 (n=84)
|
-1.33 units on a scale
Standard Deviation 2.19
|
|
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Total score, Week 24 (n=84)
|
-1.38 units on a scale
Standard Deviation 2.18
|
SECONDARY outcome
Timeframe: BaselinePopulation: ITT population; n=number of participants assessed for the specified parameter.
Participants were ask to rate their efficiency in working on a scale of of 0 to 10 (0=very worse, 10=as usual). Overall efficiency score was based on the first 6 items of Question 6, which is a descriptive instrument comprised of 7 items designed to evaluate the specific problems affecting production. These 7 items relate to the effect of health problems on concentration, work pace, the need to be alone, making decisions, postponing and transferring work to others. The participant can choose from 4 possible answers: (almost) never, sometimes, often and (nearly) always. Efficiency score range=6 to 24; higher scores indicate higher impairment.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=24 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Efficiency as Assessed by SF-HLQ
Efficiency in working (n=21)
|
6.3 units on a scale
Standard Deviation 2.4
|
|
Efficiency as Assessed by SF-HLQ
Efficiency score (n=24)
|
10.1 units on a scale
Standard Deviation 3.2
|
SECONDARY outcome
Timeframe: BaselinePopulation: ITT population; n=number of participants assessed for the specified parameter.
Participants were ask to rate their efficiency in working on a scale of of 0 to 10 (0=very worse, 10=as usual). Overall efficiency score was based on the first 6 items of Question 6, which is a descriptive instrument comprised of 7 items designed to evaluate the specific problems affecting production. These 7 items relate to the effect of health problems on concentration, work pace, the need to be alone, making decisions, postponing and transferring work to others. The participant can choose from 4 possible answers: (almost) never, sometimes, often and (nearly) always. Efficiency score range=6 to 24; higher scores indicate higher impairment. Change from baseline was only calculated for participants who completed the questionnaire at all times (baseline, Week 12 and Week 24). A negative change from baseline indicates improvement.
Outcome measures
| Measure |
Tocilizumab 8 mg/kg
n=24 Participants
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Change From Baseline to Weeks 12 and 24 in Efficiency as Assessed by SF-HLQ
Efficiency in working, Week 12 (n=21)
|
2.0 units on a scale
Standard Deviation 2.3
|
|
Change From Baseline to Weeks 12 and 24 in Efficiency as Assessed by SF-HLQ
Efficiency in working, Week 24 (n=21)
|
2.2 units on a scale
Standard Deviation 2.4
|
|
Change From Baseline to Weeks 12 and 24 in Efficiency as Assessed by SF-HLQ
Efficiency score, Week 12 (n=24)
|
-2.3 units on a scale
Standard Deviation 3.0
|
|
Change From Baseline to Weeks 12 and 24 in Efficiency as Assessed by SF-HLQ
Efficiency score, Week 24 (n=24)
|
-2.7 units on a scale
Standard Deviation 3.0
|
Adverse Events
Tocilizumab 8 mg/kg
Serious adverse events
| Measure |
Tocilizumab 8 mg/kg
n=105 participants at risk
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
General disorders
Chest pain
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Pneumonia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Vascular disorders
Deep Vein Thrombosis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
Other adverse events
| Measure |
Tocilizumab 8 mg/kg
n=105 participants at risk
Participants received tocilizumab 8 mg/kg (maximum dose 800 mg) IV once every 4 weeks for a total of 6 infusions.
|
|---|---|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
2.9%
3/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Blood and lymphatic system disorders
Leukopenia
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Cardiac disorders
Palpitations
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Ear and labyrinth disorders
Vertigo
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Abdominal pain
|
2.9%
3/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
2.9%
3/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Diarrhoea
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Dyspepsia
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Frequent bowel movements
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Haematochezia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Nausea
|
4.8%
5/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Stomatitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Gastrointestinal disorders
Vomiting
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
General disorders
Asthenia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
General disorders
Discomfort
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
General disorders
Fatigue
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
General disorders
Oedema peripheral
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
General disorders
Pyrexia
|
2.9%
3/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Immune system disorders
Anaphylactic reaction
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Immune system disorders
Hypersensitivity
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Abscess
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Bronchitis
|
3.8%
4/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Candidiasis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Folliculitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Gastroenteritis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Gastrointestinal infection
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Herpes simplex
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Herpes zoster
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Influenza
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Laryngitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Mastitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Nasopharyngitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Pharyngitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Respiratory tract infection
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Sinusitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Infections and infestations
Skin infection
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Injury, poisoning and procedural complications
Fractured coccyx
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Alanine aminotransferase increased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Aspartate aminotransferase increased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Blood cholesterol increased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Blood triglycerides increased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Heart rate increased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Lipids increased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Neutrophil count decreased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Platelet count decreased
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Transaminases abnormal
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Investigations
Transaminases increased
|
4.8%
5/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
5.7%
6/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiolipoma
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gammopathy
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic haemangioma rupture
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Nervous system disorders
Dizziness
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Nervous system disorders
Epilepsy
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Nervous system disorders
Headache
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Reproductive system and breast disorders
Metrorrhagia
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
2.9%
3/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Skin and subcutaneous tissue disorders
Pigmentation disorder
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
2.9%
3/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Surgical and medical procedures
Bunion operation
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Vascular disorders
Hypertension
|
1.9%
2/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Vascular disorders
Hypertensive crisis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
|
Vascular disorders
Phlebitis
|
0.95%
1/105 • Adverse events (AEs) were collected through the entire study period.
Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER